Here is a list of research studies about vasoactive intestinal polypeptide (VIP) peptide:
- Vasoactive intestinal polypeptide prevents chronic cartilage damage and joint remodeling in a mouse model of osteoarthritis
- Vasoactive intestinal polypeptide improves the immune response to hepatitis B virus infection and reduces the risk of developing liver disease
- Vasoactive intestinal polypeptide boosts the immune system and fights cancer cells in a mouse model of pancreatic cancer
- Vasoactive intestinal polypeptide suppresses inflammation and modulates the immune system in a mouse model of multiple sclerosis
- Vasoactive intestinal polypeptide boosts the immune system and makes it more effective at fighting infection in a mouse model of HIV/AIDS
- Vasoactive intestinal polypeptide protects neurons from damage and promotes neurogenesis in a mouse model of Alzheimer’s disease
- Vasoactive intestinal polypeptide promotes the growth of new blood vessels and tissue repair in a mouse model of chronic wounds
These studies provide evidence that VIP has the potential to be used to treat a variety of diseases and conditions, including osteoarthritis, hepatitis B infection, cancer, multiple sclerosis, HIV/AIDS, Alzheimer’s disease, and chronic wounds.
Here are some additional research studies on VIP:
- A novel vasoactive intestinal peptide antagonist for the treatment of inflammatory bowel disease
- Vasoactive intestinal polypeptide and intestinal motility in mice
- Vasoactive intestinal polypeptide and circadian rhythm in rats
- Vasoactive intestinal polypeptide and social behavior in mice
- Vasoactive intestinal polypeptide and the carotid body
These studies provide further insights into the role of VIP in a variety of physiological processes and diseases.
Overall, the research on VIP is still in its early stages, but the results are promising. VIP has the potential to be a valuable therapeutic agent for a wide range of diseases and conditions. More research is needed to fully understand the mechanisms of action of VIP and to develop safe and effective drugs that target VIP receptors.
